KR910011253A - Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제 - Google Patents

Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제 Download PDF

Info

Publication number
KR910011253A
KR910011253A KR1019900021355A KR900021355A KR910011253A KR 910011253 A KR910011253 A KR 910011253A KR 1019900021355 A KR1019900021355 A KR 1019900021355A KR 900021355 A KR900021355 A KR 900021355A KR 910011253 A KR910011253 A KR 910011253A
Authority
KR
South Korea
Prior art keywords
edrf
efficacy
production
block
effective amount
Prior art date
Application number
KR1019900021355A
Other languages
English (en)
Other versions
KR950005866B1 (ko
Inventor
브라께 삐에르
샤브리에 드 라소니에르 삐에르-에띠엔느
귈롱 쟝-미쉘
오게뜨 미쉘
Original Assignee
게라르 보푸르
소시에떼 드 꽁세이으 드 르셰르셰 에 다쁠리까시옹 시앙띠피끄(에스.세.에흐.아.에스.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게라르 보푸르, 소시에떼 드 꽁세이으 드 르셰르셰 에 다쁠리까시옹 시앙띠피끄(에스.세.에흐.아.에스.) filed Critical 게라르 보푸르
Publication of KR910011253A publication Critical patent/KR910011253A/ko
Application granted granted Critical
Publication of KR950005866B1 publication Critical patent/KR950005866B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

내용 없음

Description

EDRF 효능 똔느 그 생성을 차단하는 쇽 치료용 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 하기식의 화합물 유효량을 필수성분으로 함유함이 특징인 환류법에 의해 쇽 상태를 치료하기 위한 치료조성물.
    식중, R1및 R4는 H, CH3또는 C2H5이고 R2는 H 또는 NO2이고 R3는 NHR4, CH3또는 C2H5이다.
  2. 제1항에 있어서 1시간 동안 환류시키기 위한 지정 화합물의 유효량이 10-500mg인 조성물.
  3. 인도메타신 및 아스피린 중에서 선택되는 시클로옥시게나제의 차단제 및 하기 식의 화합물의 혼합물 유효량을 필수 성분으로서 함유함이 특징인 환류법에 의해 쇽 상태를 치료하기 위한 치료 조성물.
    식중, R1및 R4는 H, CH3또는 C2H5이고 R2는 H 또는 NO2이고 R3는 NHR4, CH3또는 C2H5이다.
  4. 제2항에 있어서 1시간 동안 환류시키기 위한 상기 혼합물의 유효량이 지정 화하물 10-100mg 및 인도메타신 0.1-1mg 또는 아스피린 2-200mg 또는 기타다른 시클로옥시게나제의 차단제 적당량으로 이루어진 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900021355A 1989-12-22 1990-12-21 Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제 KR950005866B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR89290761 1989-12-22
GB898929076A GB8929076D0 (en) 1989-12-22 1989-12-22 Treatment of shock by blocking agents of edrf effect or formation
GB89-29076.1 1989-12-22

Publications (2)

Publication Number Publication Date
KR910011253A true KR910011253A (ko) 1991-08-07
KR950005866B1 KR950005866B1 (ko) 1995-06-02

Family

ID=10668428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900021355A KR950005866B1 (ko) 1989-12-22 1990-12-21 Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제

Country Status (21)

Country Link
US (1) US5081148A (ko)
JP (1) JP2706578B2 (ko)
KR (1) KR950005866B1 (ko)
AT (1) AT403122B (ko)
AU (1) AU629777B2 (ko)
BE (1) BE1005531A5 (ko)
CA (1) CA2032904C (ko)
CH (1) CH681692A5 (ko)
DE (1) DE4041283C2 (ko)
DK (1) DK176168B1 (ko)
FR (1) FR2656220B1 (ko)
GB (2) GB8929076D0 (ko)
HK (1) HK134693A (ko)
IE (1) IE64403B1 (ko)
IT (1) IT1246511B (ko)
LU (1) LU87867A1 (ko)
MY (1) MY105328A (ko)
NL (1) NL194717C (ko)
OA (1) OA09337A (ko)
SE (1) SE504922C2 (ko)
ZA (1) ZA9010004B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE468881B (sv) * 1991-01-09 1993-04-05 Kabi Pharmacia Ab Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5585402A (en) * 1992-12-23 1996-12-17 Glaxo Wellcome Inc. Nitric oxide synthase inhibitors
US5436270A (en) * 1993-04-07 1995-07-25 National Science Council Method for protecting against endotoxin-induced shock
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition
GB9312761D0 (en) * 1993-06-21 1993-08-04 Wellcome Found Amino acid derivatives
US6090846A (en) * 1994-06-01 2000-07-18 Glaxo Wellcome Inc. Substituted urea and isothiourea derivatives as no synthase inhibitors
US6225305B1 (en) 1993-10-04 2001-05-01 Glaxo Wellcome Inc. Substituted urea and isothiorea derivatives as no synthase inhibitors
US6297276B1 (en) 1993-10-04 2001-10-02 Glaxosmithkline Substituted urea and isothiourea derivatives as no synthase inhibitors
JPH09504028A (ja) * 1993-10-21 1997-04-22 ジー．ディー．サール アンド カンパニー 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体
US5821267A (en) * 1993-10-21 1998-10-13 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
GB9404400D0 (en) * 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
ATE195933T1 (de) * 1994-03-10 2000-09-15 Searle & Co L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
US5684008A (en) 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
FR2727111B1 (fr) * 1994-11-21 1997-01-17 Hoechst Lab Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
EP0799051B1 (en) * 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
FR2730930B1 (fr) 1995-02-27 1997-04-04 Oreal Utilisation d'inhibiteurs de no-synthase pour diminuer l'effet irritant cutane de produits utilises dans le domaine cosmetique ou pharmaceutique
GB9504350D0 (en) * 1995-03-04 1995-04-26 Sod Conseils Rech Applic Arginine derivatives
KR100442561B1 (ko) * 1995-04-20 2004-10-14 지.디. 썰 엘엘씨 ５산화２질소신타아제의억제제로유용한환상아미디노제
US5830917A (en) * 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
BR9509985A (pt) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5981511A (en) * 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US6620848B2 (en) 1997-01-13 2003-09-16 Smithkline Beecham Corporation Nitric oxide synthase inhibitors
US6369272B1 (en) 1997-01-13 2002-04-09 Glaxosmithkline Nitric oxide synthase inhibitors
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
JP2002517502A (ja) 1998-06-10 2002-06-18 ジー・ディー・サール・アンド・カンパニー 複素二環状及び三環状一酸化窒素シンターゼ阻害剤
US6344473B1 (en) 2000-08-07 2002-02-05 G.D. Searle & Co. Imidazoles useful as nitric oxide synthase inhibitors
CA2552195C (en) 2003-12-30 2012-01-24 Vasopharm Biotech Gmbh 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931921A (en) * 1960-12-22 1963-07-24 Lab Roques Therapeutic compositions intended for the treatment of any hepatic malfunctionings
GB1195612A (en) * 1967-04-13 1970-06-17 Sumitomo Chemical Co An Injection
FR2115060A1 (en) * 1970-11-26 1972-07-07 Metabio Freeze-dried acetylsalicylates of lysine and arginine - easily prepd derivs of aspirin
CA1029660A (en) * 1973-06-01 1978-04-18 Kyowa Hakko Kogyo Co. Prevention of gastric lesions
FR2320759A1 (fr) * 1975-08-11 1977-03-11 Union Pharma Scient Appl Solution d'acide acetylsalicylique extemporanee injectable
IT1127321B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizione farmaceutiche aventi specifiche proprieta' terapeutiche nei confronti dell'edema polmonare acuto,di alcuni stati di shock e dell'iperfibrinolisi
IT1127322B (it) * 1979-12-28 1986-05-21 Italfarmaco Spa Composizioni farmaceutiche con esaltazione dell'attivita' terapeutica di cortisonici
JPS5781409A (en) * 1980-11-10 1982-05-21 Toko Yakuhin Kogyo Kk External plaster
JPS57197211A (en) * 1981-05-28 1982-12-03 Sumitomo Chem Co Ltd Useful eye drop composition
JPS57200361A (en) * 1981-06-03 1982-12-08 Sumitomo Chem Co Ltd "indomethacin(r)" pharmaceutical with low irritant action
JPH0236570B2 (ja) * 1985-05-30 1990-08-17 Toko Yakuhin Kogyo Kk Shoenchintsunankozai
JPS6239524A (ja) * 1985-08-13 1987-02-20 Toko Yakuhin Kogyo Kk 消炎鎮痛軟膏剤
IT1201511B (it) * 1985-12-23 1989-02-02 Italfarmaco Spa Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono
AU1489688A (en) * 1987-02-20 1988-09-14 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment

Also Published As

Publication number Publication date
AU629777B2 (en) 1992-10-08
IT9022413A0 (it) 1990-12-18
HK134693A (en) 1993-12-17
NL194717C (nl) 2003-01-07
CH681692A5 (ko) 1993-05-14
AU6837690A (en) 1991-06-27
JP2706578B2 (ja) 1998-01-28
LU87867A1 (fr) 1991-05-07
JPH04364124A (ja) 1992-12-16
FR2656220B1 (fr) 1995-01-13
AT403122B (de) 1997-11-25
DK304190D0 (da) 1990-12-21
DK304190A (da) 1991-06-23
GB2240041B (en) 1993-09-01
NL194717B (nl) 2002-09-02
CA2032904A1 (en) 1991-06-23
FR2656220A1 (fr) 1991-06-28
CA2032904C (en) 1996-01-02
US5081148A (en) 1992-01-14
ATA260690A (de) 1997-04-15
GB2240041A (en) 1991-07-24
BE1005531A5 (fr) 1993-09-28
IE64403B1 (en) 1995-08-09
SE504922C2 (sv) 1997-05-26
ZA9010004B (en) 1991-10-30
MY105328A (en) 1994-09-30
KR950005866B1 (ko) 1995-06-02
DE4041283A1 (de) 1991-06-27
NL9002720A (nl) 1991-07-16
IT1246511B (it) 1994-11-19
IT9022413A1 (it) 1991-06-23
SE9003974L (sv) 1991-06-23
GB8929076D0 (en) 1990-02-28
DE4041283C2 (de) 2000-07-13
OA09337A (fr) 1992-09-15
SE9003974D0 (sv) 1990-12-12
DK176168B1 (da) 2006-11-13
IE904592A1 (en) 1991-07-03
GB9028013D0 (en) 1991-02-13

Similar Documents

Publication Publication Date Title
KR910011253A (ko) Edrf 효능 또는 그 생성을 차단하는 쇽 치료용 약제
KR920021556A (ko) 라파 마이신 이량체
DE68914439T2 (de) Schmierölzusammensetzungen.
KR910004187A (ko) 세트랄린을 사용한 조기사정의 치료방법
DE68900492D1 (de) Schmieroelzusammensetzung.
DE58901932D1 (de) Schmieroelzusammensetzung.
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
DE68918552D1 (de) Schmierölzusammensetzung.
KR920700695A (ko) 비스테로이드계 소염진통제를 함유하는 수중유형 유화 조성물
KR890014107A (ko) 백금 화학 요법약제
ATE255895T1 (de) Zusammensetzungzur verminderung von schmerzen, die ein nicht narkotischen analgetika und ein analgetikabekräftiger enthält
KR920016089A (ko) 제i형 당뇨병의 치료방법
KR890014536A (ko) 축합 퀴놀린계 화합물, 축합 아크리딘계 화합물 및 그의 제조방법과 그것을 함유하는 항암제 조성물
ES2191763T3 (es) Inhibidor del desarrollo de dependencia/tolerancia a un agente analgesico narcotico.
KR920017668A (ko) 암 전이 억제 또는 예방 방법 및 이를 위한 제제
KR880001596A (ko) 디하이드로피리딘 화합물-함유 뇌기능이상 치료제
DE68919907T2 (de) Brennölzusammensetzungen.
KR900701262A (ko) 췌장염 등에 대한 치료제
KR890003793A (ko) 3'-데메톡시에피포도필로톡신 배당체의 유도체
KR910005860A (ko) 항간질환성 조성물
DE68911129D1 (de) Schmierölzusammensetzung.
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물
KR880009644A (ko) 궤양성 대장질환 치료용 약한 조성물
KR830005188A (ko) 혈당강하성 구아닐 아미딘의 제조방법
KR920000327A (ko) 비스(3,5-디-알킬-4- 히드록시페닐티오) 메탄을 유효 성분으로 함유하는 고트리글리세리드혈증 치료용 제약 조성물

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee